TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page1/Line 2-3	TITLE
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page2/Line 34-57	Abstract
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page4-5/Line 79-122	Introduction, Paragraph1-4
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page5/Line 123-131	Introduction, Paragraph 4-5
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable.	Page5-6/Line 135-138	2.1 Data Collection
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page6/Line 137-138	2.1 Data Collection
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Page6/Line 139-140	2.1 Data Collection
	5b	D;V	Describe eligibility criteria for participants.	Page 6/Line 139-140	2.1 Data Collection
	5c	D;V	Give details of treatments received, if relevant.	NA, No detailed	NA
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page7-8/Line 188-193	2.4 Construction and validation of the prognostic model PLPI
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	Page9/Line 236-240	2.8 Statistical Analysis
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page6-7/Line 143-179	As & 2.3 Identification of the prognostic pyroptosis-related lncRNA pairs
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	Page9/Line 236-240	2.8 Statistical Analysis
Sample size	8	D;V	Explain how the study size was arrived at.	Page6/Line 136-137	2.1 Data Collection

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Page6/Line 139-140	2.1 Data Collection
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Page6-7/Line 143-187	n of the prognostic model PLPI
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page7-8/Line 181-198	2.4 Construction and validation of the prognostic model PLPI
	10c	V	For validation, describe how the predictions were calculated.	Page7-8/Line 191-193	ation of the prognostic model PLPI
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page8-9/Line 193-234	s & 2.7 Drug and mutation Analyses
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	NA, no model updating was arisen from the validatio	NA
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	Page7-8/Line 191-193	ation of the prognostic model PLPI
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Page11/Line 285-286	3.3 Construction and validation of PLPI based on the DEPR-lncRNA pairs
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page10/Line 274-275	3.3 Construction and validation of PLPI based on the DEPR-lncRNA pairs
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Page11/Line 291-292	3.3 Construcrion and validation of PLPI based on the DEPR-lncRNA pairs
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Page10-11/Line 273-287	3.3 Construction and validation of PLPI based on the DEPR-lncRNA pairs
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	Page6/Line 136-137	2.1 Data Collection
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Page11-14/Line 298-344	nts and somatic mutation analyses
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Page10/Line 272-274	3.3 Construction and validation of PLPI based on the DEPR-lncRNA pairs
	15b	D	Explain how to the use the prediction model.	Page16-17/Line 455-458	5 Conclusion
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Page10-11/Line 275-297	3.3 Construction and validation of PLPI based on the DEPR-lncRNA pairs
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	NA, the model has not been updated	NA
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page16/Line 448-452	4. Discussion

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Page13-14/Line 355-381	4. Discussion
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page16/Line 382-442	4. Discussion
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Page16/Line 443-448	4. Discussion
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Page5/Line 142	2.1 Data Collection
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Page17/Line 501	Acknowledgements

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article Information: https://dx.doi.org/10.21037/tcr-23-1804
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.